Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.

• Status: Completed
• Trial end date: 2009-03-10
• Target enrollment: 0
• Participant gender: All

Summary

Dapsone is a drug that has been used clinically for several decades due to its anti-infective effect, making it widely available. Its neuroprotective effects have been found through its glutamate receptors antagonistic effect. Their main objective was to study the neuroprotective properties in patients with aneurysmal subarachnoid hemorrhage and high-risk factors for the development of cerebral vasospasm. Both the placebo and the dapsone used in this clinical trial were provided by the institution's neurochemistry laboratory.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
• Treatments: Aluminum Hydroxide; Dapsone

Criteria

Inclusion Criteria:

• Participants presented with aneurysmal subarachnoid hemorrhage.

• Candidates to aneurysm occlusion.

• Fisher scale grade III or IV.

Exclusion Criteria:

• Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.

• Anemia at admission.

• Known allergy to sulfones or sulfas.

• Severe systemic disease (renal or hepatic failure).